Dartmouth researchers have found a machine learning method that can predict the likelihood that a high-risk type of breast lesion is cancerous, potentially saving some women from unnecessary surgeries and overtreatment.
Post Tagged with: "Norris Cotton Cancer Center"
Steven D. Leach, MD, director of the Dartmouth-Hitchcock Norris Cotton Cancer Center and the Preston T. and Virginia R. Kelsey Distinguished Chair in Cancer at the Geisel School of Medicine at Dartmouth, has been named a Fellow of the American Association for the Advancement of Science.
Geisel professor and surgeon Richard Barth, MD, teamed up with two Thayer engineers to dramatically improve the accuracy of breast cancer surgery.
A newly published collaborative national study finds that most women with two or three sites of cancer in a single breast can successfully complete breast conservation therapy rather than mastectomy.
Many discoveries now revolutionizing the prevention and treatment of cancer can be traced back to Dartmouth—including immunotherapies for solid tumors, the integration of palliative care with cancer care, and the identification of cancer risks from environmental toxins and behaviors.
Dartmouth study finds e-cigarette use could do more harm than good by substantially increasing the number of adolescents and young adults who eventually become cigarette smokers and marginally decreasing the number of adult cigarette smokers who quit.
Gregory Tsongalis, PhD, a professor of pathology at Dartmouth’s Geisel School of Medicine and director of the Laboratory for Clinical Genomics and Advanced Technology at Dartmouth-Hitchcock Medical Center and Norris Cotton Cancer Center, has received the Jeffrey A. Kant Leadership Award from the Association for Molecular Pathology (AMP).
Experiences such as working as a volunteer on medical mission trips to Honduras and practicing as an oncology nurse in Arizona helped Meghan Bullock ’20 decide that medical school was the right path for her.
Dartmouth-led research is in early phase drug discovery and finds promising therapeutic leads after targeting vulnerabilities in nervous system tumors, including glioblastoma.
More than $12 million over five years has been awarded for research collaboration to more precisely determine lung cancer risk and improve screening.